Grand RoundsArchive

Nephrology

Specializing in kidney care and the treatment of diseases of the kidneys.

21 editions available

View Latest Edition(May 2, 2026)

2026

May 2, 2026Latest
Targeted risk-factor control, drug exposure phenotypes, and outcome stratification in CKD and transplant patients
May 2, 2026|5 articles
April 25, 2026
Actionable nephrology updates: dialysis time, CKD in aging, AKI prevention, diabetes phenotypes, and transplant risk
April 25, 2026|9 articles
April 18, 2026
New evidence reshaping risk prediction and treatment decisions across CKD, ESKD, and transplant nephrology
April 18, 2026|9 articles
April 11, 2026
Evolving risks, trajectories, and treatments across the kidney disease spectrum
April 11, 2026|9 articles
April 4, 2026
Targeted genetics, refined immunosuppression, and streamlined dialysis care inform everyday nephrology decisions
April 4, 2026|9 articles
March 28, 2026
New data shaping nephrology practice: APRIL blockade in IgAN, DKD drug failure, folate in CKD, and pragmatic strategies for stones, RAASi, albuminuria, cancer nephrotoxicity, and frail octogenarians
March 28, 2026|8 articles
March 21, 2026
Targeted RAASi use, inflammation markers, and early kidney protection strategies sharpen nephrology decision-making
March 21, 2026|9 articles
March 14, 2026
New data refine cardiorenal therapy, anemia management, transplant equity, and biomarker-guided risk across nephrology
March 14, 2026|10 articles
March 7, 2026
Targeted therapies, access strategies, and care models are reshaping kidney and transplant outcomes
March 7, 2026|9 articles
February 28, 2026
New evidence refining CKD detection, dialysis practice, and renoprotective therapy across the kidney disease spectrum
February 28, 2026|10 articles
February 21, 2026
Implementing KDIGO 2024, GN decision-making, and cardiorenal risk: new data for nephrology practice
February 21, 2026|8 articles
February 14, 2026
New data on post-AKI SGLT2i use, CKD biomarkers, genetics, and practice gaps in nephrology
February 14, 2026|9 articles
February 7, 2026
Cardiorenal risk, prognostication, and therapeutics across the CKD spectrum
February 7, 2026|9 articles
January 31, 2026
Focused Updates in CKD Progression, Transplant Access, and Glomerular Disease
January 31, 2026|10 articles
January 24, 2026
New data reshaping kidney risk stratification, therapeutics, and systems of care
January 24, 2026|9 articles
January 17, 2026
Targeting BP, diabetes, complement, and access to curb kidney and vascular risk
January 17, 2026|10 articles
January 10, 2026
Targeted refinements in CKD anemia care, kidney risk stratification, and dialysis delivery
January 10, 2026|9 articles

Nephrology

2026

Targeted risk-factor control, drug exposure phenotypes, and outcome stratification in CKD and transplant patients

Actionable nephrology updates: dialysis time, CKD in aging, AKI prevention, diabetes phenotypes, and transplant risk

New evidence reshaping risk prediction and treatment decisions across CKD, ESKD, and transplant nephrology

Evolving risks, trajectories, and treatments across the kidney disease spectrum

Targeted genetics, refined immunosuppression, and streamlined dialysis care inform everyday nephrology decisions

New data shaping nephrology practice: APRIL blockade in IgAN, DKD drug failure, folate in CKD, and pragmatic strategies for stones, RAASi, albuminuria, cancer nephrotoxicity, and frail octogenarians

Targeted RAASi use, inflammation markers, and early kidney protection strategies sharpen nephrology decision-making

New data refine cardiorenal therapy, anemia management, transplant equity, and biomarker-guided risk across nephrology

Targeted therapies, access strategies, and care models are reshaping kidney and transplant outcomes

New evidence refining CKD detection, dialysis practice, and renoprotective therapy across the kidney disease spectrum

Implementing KDIGO 2024, GN decision-making, and cardiorenal risk: new data for nephrology practice

New data on post-AKI SGLT2i use, CKD biomarkers, genetics, and practice gaps in nephrology

Cardiorenal risk, prognostication, and therapeutics across the CKD spectrum

Focused Updates in CKD Progression, Transplant Access, and Glomerular Disease

New data reshaping kidney risk stratification, therapeutics, and systems of care

Targeting BP, diabetes, complement, and access to curb kidney and vascular risk

Targeted refinements in CKD anemia care, kidney risk stratification, and dialysis delivery

2025

Dialysis initiation, infection prevention, transplant expansion, and emerging therapeutics: concise updates for nephrologists

GBCA safety in advanced CKD, resistant hypertension updates, and emerging interventional and molecular tools in nephrology

Targeted therapies in CKD and glomerular disease: separating mechanistic promise from clinical payoff

New mechanistic and interventional data reshaping nephrology practice from AKI prevention to DKD and glomerular disease

Nephrology

2026

Targeted risk-factor control, drug exposure phenotypes, and outcome stratification in CKD and transplant patients

Actionable nephrology updates: dialysis time, CKD in aging, AKI prevention, diabetes phenotypes, and transplant risk

New evidence reshaping risk prediction and treatment decisions across CKD, ESKD, and transplant nephrology

Evolving risks, trajectories, and treatments across the kidney disease spectrum

Targeted genetics, refined immunosuppression, and streamlined dialysis care inform everyday nephrology decisions

New data shaping nephrology practice: APRIL blockade in IgAN, DKD drug failure, folate in CKD, and pragmatic strategies for stones, RAASi, albuminuria, cancer nephrotoxicity, and frail octogenarians

Targeted RAASi use, inflammation markers, and early kidney protection strategies sharpen nephrology decision-making

New data refine cardiorenal therapy, anemia management, transplant equity, and biomarker-guided risk across nephrology

Targeted therapies, access strategies, and care models are reshaping kidney and transplant outcomes

New evidence refining CKD detection, dialysis practice, and renoprotective therapy across the kidney disease spectrum

Implementing KDIGO 2024, GN decision-making, and cardiorenal risk: new data for nephrology practice

New data on post-AKI SGLT2i use, CKD biomarkers, genetics, and practice gaps in nephrology

Cardiorenal risk, prognostication, and therapeutics across the CKD spectrum

Focused Updates in CKD Progression, Transplant Access, and Glomerular Disease

New data reshaping kidney risk stratification, therapeutics, and systems of care

Targeting BP, diabetes, complement, and access to curb kidney and vascular risk

Targeted refinements in CKD anemia care, kidney risk stratification, and dialysis delivery

2025

Dialysis initiation, infection prevention, transplant expansion, and emerging therapeutics: concise updates for nephrologists

GBCA safety in advanced CKD, resistant hypertension updates, and emerging interventional and molecular tools in nephrology

Targeted therapies in CKD and glomerular disease: separating mechanistic promise from clinical payoff

New mechanistic and interventional data reshaping nephrology practice from AKI prevention to DKD and glomerular disease